Bayer submits new Levitra formulation for EU registration

Published: 19-Aug-2009

Bayer Schering Pharma has applied to register a new formulation of Levitra (vardenafil HCI) in the European Union. The orodispersible tablet for treating erectile dysfunction contains 10mg vardenafil and provides a discreet and convenient way for men to take the tablet as it dissolves on the tongue in seconds.


Bayer Schering Pharma has applied to register a new formulation of Levitra (vardenafil HCI) in the European Union. The orodispersible tablet for treating erectile dysfunction contains 10mg vardenafil and provides a discreet and convenient way for men to take the tablet as it dissolves on the tongue in seconds.

"With the submission of this new formulation of Levitra, we have reached another important strategic milestone in the development of innovative and easy-to-use men's health products," said Jean-Philippe Milon, head of Bayer Schering Pharma's general medicine business unit.

The efficacy and safety of Levitra 10mg orodispersible tablet have been demonstrated in two clinical Phase III studies. The new formulation has shown the same efficacy and safety as the currently available tablet.

You may also like